New 'Smarter' GLP-1 drug enters first human tests for blood sugar control
NCT ID NCT07327281
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase trial tests a new drug called TQF3250 in 66 healthy adults with high blood sugar. The drug is designed to activate only certain parts of the GLP-1 receptor, aiming for better blood sugar control with fewer side effects. The main goal is to check safety and how the body handles the drug, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERGLYCEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Drum Tower Hospital Affiliated to Nanjing University School of Medicine
RECRUITINGNanjing, Jiangsu, 210008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQF3250 capsule (biased GLP-1 receptor agonist)
What this could lead to
If successful, this could lead to a new treatment option for high blood sugar with fewer side effects than current GLP-1 drugs.
What could go wrong
This is a very early Phase 1 trial in only 66 healthy people, so it is too soon to know if it works or is safe. Side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.